Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q4 FY22 results · Jan–Mar 2022
Tatva Chintan Pharma Chem reported revenue from operations of ₹98.53 crore and net profit of ₹17.51 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 98.53 | — | — | 104.67 | −5.9% |
| Other income | 0.35 | — | — | 4.72 | −92.5% |
| Total income | 98.89 | — | — | 109.39 | −9.6% |
| Profit before tax | 18.98 | — | — | 25.47 | −25.5% |
| Net profit for the period | 17.51 | — | — | 22.81 | −23.2% |
| EPS, basic (₹) | 7.90 | — | — | 10.29 | −23.2% |
| Net margin (%) | 17.8 | — | 21.8 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 101.88 | — | — | 101.59 | +0.3% |
| Other income | 1.19 | — | — | 5.08 | −76.6% |
| Total income | 103.07 | — | — | 106.67 | −3.4% |
| Profit before tax | 19.96 | — | — | 24.77 | −19.4% |
| Net profit for the period | 18.89 | — | — | 22.43 | −15.8% |
| EPS, basic (₹) | 8.52 | — | — | 10.12 | −15.8% |
| Net margin (%) | 18.5 | — | 22.1 |
Consolidated
- Filed with BSE
- 26 Apr 2022, 16:01 IST
- Board meeting
- 25 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 Apr 2022, 16:01 IST
- Board meeting
- 25 Apr 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE